Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients

This publication has 39 references indexed in Scilit:

• Ultradeep sequencing detects GNAQ and GNA11 mutations in cell‐free DNA from plasma of patients with uveal melanoma
  Cancer Medicine, 2013
• Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era
  PLOS ONE, 2013
• STAR: ultrafast universal RNA-seq aligner
  Bioinformatics, 2012
• EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience
  Blood, 2012
• A framework for variation discovery and genotyping using next-generation DNA sequencing data
  Nature Genetics, 2011
• The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
  Genome Research, 2010
• Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
  The Journal of Molecular Diagnostics, 2009
• P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
  Journal of Hematology & Oncology, 2008
• ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia
  Journal of Clinical Oncology, 2005
• Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
  Blood, 2003